Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000092938

Apexbio Technology LLC Leflunomide 75706-12-6 10mM (in 1mL DMSO)
SDP

Catalog No. 5000092938
Encompass_Preferred

Leflunomide (CAS 75706-12-6) is a small-molecule agonist targeting the aryl hydrocarbon receptor (AHR) pathway It is designed to modulate AHR signaling thereby enhancing regulatory T cell (Treg) numbers altering inflammatory cytokine profiles and influencing immune responses Leflunomide exerts its biological activity primarily through metabolic conversion to its active metabolite Teriflunomide (A771726) which mediates immunosuppressive effects It enhances IL-10 production and suppresses IL-17 and IL-23 secretion In cell-based studies leflunomide demonstrates anti-proliferative efficacy in human medullary thyroid carcinoma cells (MTC-TT) with IC50 values ranging from approximately 30 to 50 M depending on specific assay conditions Based on these pharmacological properties leflunomide holds research potential in ischemia-reperfusion renal injury sepsis-induced intestinal oxidative stress and tumor proliferation inhibition models

Catalog No. 50-000-92938 Supplier Apexbio Technology LLC Supplier No. A28525.1
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Leflunomide (CAS 75706-12-6) is a small-molecule agonist targeting the aryl hydrocarbon receptor (AHR) pathway It is designed to modulate AHR signaling thereby enhancing regulatory T cell (Treg) numbers altering inflammatory cytokine profiles and influencing immune responses Leflunomide exerts its biological activity primarily through metabolic conversion to its active metabolite Teriflunomide (A771726) which mediates immunosuppressive effects It enhances IL-10 production and suppresses IL-17 and IL-23 secretion In cell-based studies leflunomide demonstrates anti-proliferative efficacy in human medullary thyroid carcinoma cells (MTC-TT) with IC50 values ranging from approximately 30 to 50 M depending on specific assay conditions Based on these pharmacological properties leflunomide holds research potential in ischemia-reperfusion renal injury sepsis-induced intestinal oxidative stress and tumor proliferation inhibition models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.